Curaleaf Holdings has criticized Aurora Cannabis for denying it due diligence access while allowing other potential buyers, despite Curaleaf's binding offer that includes a 217% premium on an ex-cash basis. Curaleaf argues Aurora's board is not acting in shareholders' best interests by obstructing engagement and misrepresenting facts about the offer's value and conditions. The dispute highlights tensions in the ongoing hostile takeover bid, with Curaleaf ready to negotiate if given access. This battle could impact shareholder value and the future of both cannabis companies.
Aurora Cannabis (ACB) is trading at USD 3.99 on Pluang as of Oct 19, 2026 18:12 WIB, holding steady with no change in the last day. This price sits closer to its 52-week low of USD 2.58 than its high of USD 5.57, reflecting a wide range over the year. The ongoing takeover dispute with Curaleaf could influence future price movements given the current market cap of $251.55 million and a typical hold time of 26 days on the platform.
